The Evolving Role of Serial Non-Invasive Tests in Predicting HCC in MASLD

The letter to the editor by Kang et al. provides insightful data into the association between longitudinal changes in Fatty Liver Index (FLI), a non-invasive test (NIT) that measures steatosis, and the incidence of hepatocellular carcinoma (HCC) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, previously referred to as nonalcoholic fatty liver disease or NAFLD). This evidence aligns with our findings, 1 which support the integration of serial NIT measurements of liver disease severity as a means to risk stratify and surveil the growing population affected by MASLD.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research